Abstract:Abstract Intro Epigenetic changes, including altered DNA methylation, underlie the development and progression of prostate cancer (PCa). DNA methylation events are frequently seen in PCa, however, how these methylation changes are directed locally and regionally remain an important question. CTCF is a widely expressed chromatin insulator protein which plays important roles in transcriptional regulation, chromatin architecture, and the conservation of epigenetic marks. Previous work has shown that CTCF expression declines in the aging mouse prostate and in human metastatic prostate samples. It is our hypothesis that CTCF loss directs DNA methylation increases at specific loci resulting in gene expression and phenotypic advantages in cancer cells. Methods Cell lines with inducible shRNA expression targeting CTCF were created using 9E6/E7 human prostate epithelial cells and PPC1 and LNCaP cancer lines. Knockdowns were confirmed by qPCR and western blotting. DNA methylation was analyzed using MeDIP-chip, utilizing the Affymetrix Cytoscan HD Array and RNA expression analyzed using Affymetrix Human Transcriptome 2.0 Array. Bioinformatic analysis was performed in R 3.2.1 and Bioconductor 3.0. Motif analysis was performed using HOMER. Cell stress included exposure to H2O2 and CoCl2. Results We detected 9811 probes with differential methylation after CTCF knockdown (with P<0.01), of which 5,968 probes (60.1%) were hypermethylated. Of the hypermethylated probes, 417 (7%) were near gene transcription start sites and 3,361 (56.3%) were located within transcribed loci. Motif analysis indicated that CTCF target sequences were enriched in regions developing hypermethylation (P<0.01). Pyrosequencing confirmed methylation increases. RNA expression analysis with CTCF knockdown identified 1,394 transcribed loci with significantly altered expression (FDR<0.1). One-third of genes with altered transcriptional levels also contained a differentially methylated probe in its promoter or transcribed region (459/1394; 32.9%). We confirmed numerous genes with promoter hypermethylation corresponding to decreased RNA expression including CASP14, EDN1, EL, FSTL1, and WIPI1. Gene ontology indicates enrichment for anti-apoptotic genes. CTCF knockdown in epithelial and cancer cell lines led to a significantly increased survival of cells faced with hypoxia or oxidative stress. Conclusion Reduction of CTCF, an alteration that occurs in the development of advanced PCa, directs the hypermethylation of loci containing CTCF binding sites. These hypermethylated regions correspond to the transcriptional downregulation of genes involved in metabolism, ER stress, and apoptosis. CTCF knockdown results in resistance to hypoxia or oxidative stress. This study demonstrates, for the first time that CTCF acts as a master regulator to direct epigenetic events important for tumor development and progression and is a target for therapy. Citation Format: Nathan A. Damaschke, Bing Yang, Anastasia Montgomery, John Svaren, Avtar Roopra, Jianhua Luo, Sunduz Keles, David Jarrard. CTCF acts as a master regulator to direct epigenetic events important for tumor development and progression. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4434.

Tumorigenesis and Neoplastic Progression CSR 1 Suppresses Tumor Growth and Metastasis of Prostate Cancer

CSR1 suppresses tumor growth and metastasis of prostate cancer.

Csr1 Induces Cell Death Through Inactivation of Cpsf3

Upregulation of Serine Metabolism Enzyme PSAT1 Predicts Poor Prognosis and Promotes Proliferation, Metastasis and Drug Resistance of Clear Cell Renal Cell Carcinoma.

Oncogenic Activity of miR-650 in Prostate Cancer Is Mediated by Suppression of CSR1 Expression.

TET1 Suppresses Cancer Invasion by Activating the Tissue Inhibitors of Metalloproteinases.

Interaction of CSR1 with XIAP Reverses Inhibition of Caspases and Accelerates Cell Death.

SMARCC1 Suppresses Tumor Progression by Inhibiting the PI3K/AKT Signaling Pathway in Prostate Cancer

NES1/KLK10 gene represses proliferation, enhances apoptosis and down-regulates glucose metabolism of PC3 prostate cancer cells

Abstract 4434: CTCF Acts As a Master Regulator to Direct Epigenetic Events Important for Tumor Development and Progression

The role of SRC-1 in murine prostate cancinogenesis is nonessential due to a possible compensation of SRC-3/AIB1 overexpression

Combination of the NRF2 Inhibitor and Autophagy Inhibitor Significantly Inhibited Tumorigenicity of Castration-Resistant Prostate Cancer

Mir-302/367/Lats2/yap Pathway is Essential for Prostate Tumor-Propagating Cells and Promotes the Development of Castration Resistance.

Aberrant Expression of Citrate Synthase is Linked to Disease Progression and Clinical Outcome in Prostate Cancer

Abstract 3185: Expression of DNA Methyltransferase (DNMT) Induced by Transforming Growth Factor-SS (Tgf-SS) Promotes Progress of Prostate Cancer

Genome-Wide CRISPR-Cas9 Screening and Identification of Potential Genes Promoting Prostate Cancer Growth and Metastasis

Down-regulation of SLC14A1 in prostate cancer activates CDK1/CCNB1 and mTOR pathways and promotes tumor progression

Abstract A028: Dissecting the role of cellular senescence in prostate cancer initiation and immune suppression

Mesenchymal Stem Cells Overexpressing Sirt1 Inhibit Prostate Cancer Growth by Recruiting Natural Killer Cells and Macrophages

CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expression

Abstract 3085: Cholesterol sulfotransferase SULT2B1b suppresses prostate tumor growth and regulates cholesterol metabolism in prostate cancer cells